XML 137 R101.htm IDEA: XBRL DOCUMENT v3.21.2
Shareholders' equity (deficit) - Additional Information (Detail)
12 Months Ended
Jun. 30, 2020
EUR (€)
Dec. 31, 2020
EUR (€)
€ / shares
shares
Jul. 01, 2020
EUR (€)
€ / shares
shares
Dec. 31, 2019
EUR (€)
€ / shares
shares
Dec. 31, 2019
$ / shares
Dec. 31, 2018
EUR (€)
Disclosure of classes of share capital [line items]            
Stock issued during period, value, new issues € 500,000 € 0.01        
Number of shares outstanding | shares   62,908,617        
Par value per share | € / shares   € 0.01        
Number of shares value outstanding   € 629,000 € 629,000 € 1,164,000 [1]    
Share premium   € 538,695,000   € 190,945,000 [1]    
Reorganization [Member]            
Disclosure of classes of share capital [line items]            
Number of shares outstanding | shares       33,093,838    
Par value per share | $ / shares         $ 0.01  
Immatics Biotechnologies GmbH [Member]            
Disclosure of classes of share capital [line items]            
Number of shares outstanding | shares       1,163,625    
Par value per share | € / shares       € 1.00    
PIPE Financing [member] | ARYA Merger [Member]            
Disclosure of classes of share capital [line items]            
Share premium     € 327,800,000      
Ordinary Shares [member]            
Disclosure of classes of share capital [line items]            
Number of shares outstanding | shares     62,908,617      
Par value per share | € / shares     € 0.01      
Series E Share Capital [member] | Immatics Biotechnologies GmbH [Member]            
Disclosure of classes of share capital [line items]            
Share premium           € 23,600,000
[1] See Note 2 for details regarding the change in presentation of Other financial assets